Celularity Beheer

Beheer criteriumcontroles 2/4

De CEO Celularity is Bob Hariri, benoemd in Jul2021, heeft een ambtstermijn van 3.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.23M, bestaande uit 97.2% salaris en 2.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 12.95% van de aandelen van het bedrijf, ter waarde $ 4.10M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 2.8 jaar.

Belangrijke informatie

Bob Hariri

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	97.2%
Dienstverband CEO	3.3yrs
Eigendom CEO	13.0%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

Feb 14

News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts

Dec 14

Celularity: Celgene Spin-Off Developing Allogeneic Therapies

Sep 06

Analyse CEO-vergoeding

Hoe is Bob Hariri's beloning veranderd ten opzichte van Celularity's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-US$154m
Dec 31 2023	US$1m	US$1m	-US$196m
Sep 30 2023	n/a	n/a	-US$181m
Jun 30 2023	n/a	n/a	-US$83m
Mar 31 2023	n/a	n/a	US$13m
Dec 31 2022	US$5m	US$1m	US$14m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	US$31m
Mar 31 2022	n/a	n/a	-US$81m
Dec 31 2021	US$22m	US$1m	-US$100m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$188m
Mar 31 2021	n/a	n/a	-US$260m
Dec 31 2020	US$3m	US$1m	-US$208m

Compensatie versus markt: De totale vergoeding ($USD 1.23M ) Bob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).

Compensatie versus inkomsten: De vergoeding van Bob is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bob Hariri (65 yo)

3.3yrs

Tenure

US$1,234,342

Compensatie

Dr. Robert Joseph Hariri, also known as Bob, M.D., Ph.D. is a Co-Founder of Human Longevity, Inc. and serves as President of Human Longevity Cellular Therapeutics. He serves as Medical Advisor at Beyond Im...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Hariri	Founder	3.3yrs	US$1.23m	12.95% $ 4.1m
John Haines	Senior EVP	2.1yrs	US$815.82k	0.069% $ 21.7k
David Beers	Chief Financial Officer	3.3yrs	US$1.71m	0.034% $ 10.6k
Carlos Ramirez	SVP of Investor Relations	no data	geen gegevens	geen gegevens
Kyle Fletcher	Executive VP	2.3yrs	geen gegevens	0.0033% $ 1.1k
Stephen Brigido	President of Degenerative Diseases	3.3yrs	geen gegevens	0.0025% $ 794.6
Sharmila Koppisetti	Senior Vice President of Clinical Dev. Immunology & Drug Safety	2.8yrs	geen gegevens	geen gegevens
Tim Wilk	Senior Vice President of Technical Operations	1.4yrs	geen gegevens	geen gegevens
David Lemus	Treasurer	no data	geen gegevens	geen gegevens
Timothy Smith	Secretary	no data	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CELU wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Hariri	Founder	3.3yrs	US$1.23m	12.95% $ 4.1m
Richard Jay Berman	Director	less than a year	geen gegevens	geen gegevens
Diane Parks	Independent Director	2.4yrs	US$322.50k	0.11% $ 34.0k
Louis Weiner	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Dean Kehler	Independent Director	6.8yrs	US$354.75k	0.93% $ 294.5k
Peter Diamandis	Independent Director	3.3yrs	US$326.50k	0.59% $ 188.2k
Geoffrey Shiu Ling	Independent Director	1.2yrs	US$301.25k	geen gegevens
Darren Sigal	Co-Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CELU wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

Celularity Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Celularity Inc. Appoints Richard J. Berman to Its Board of Directors

High number of new and inexperienced directors

Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors

Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees

Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

High number of new and inexperienced directors

Recent updates

Celularity Inc. (NasdaqCM:CELU) acquired Rebound and its certain related assets from Sequence LifeScience, Inc. for $5.5 million.

Celularity Inc. Appoints Richard J. Berman to Its Board of Directors

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Celularity Inc. Revises Sales Guidance for the First Quarter of 2024

Celularity Inc. Revises Sales Guidance for the First Quarter of 2024

Celularity Presents Data of the Effect of Its T-Cell Platform on Multiple Hematological and Solid Tumors At the American Society of Clinical Oncology (Asco) Annual Meeting

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Celularity Inc. announced delayed annual 10-K filing

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L

Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%

High number of new and inexperienced directors

Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Genting Berhad Engages in Discussions with Celularity Inc

Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Celularity Inc. announced delayed 10-Q filing

Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees

Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Celularity Inc. to Present Data from a New Product Technology in Development for Orthopedic Applications at 7th International Conference on Orthopedics

New major risk - Share price stability

Celularity Inc. Announces Results from Exploratory Analysis of Phase 1 Data Evaluating Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn's Disease

Celularity Inc. announced delayed 10-Q filing

Price target decreased by 24% to US$8.63

Consensus revenue estimates decrease by 36%, EPS upgraded

Independent Director exercised options to buy US$822k worth of stock.

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (Ctw)

Celularity Inc. Announces the Suspends of Robert Hariri as Chairman

Price target decreased by 12% to US$9.50

Celularity Inc. Announces in A Preclinical in Vivo Study of Placental Extracellular Matrix

Celularity Inc.'s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn's Disease in Phase 1, Phase 1b/2a and Phase 1b Studies

Celularity Inc. Appoints Paul Graves as Chief Communications Officer

Consensus forecasts updated

Celularity Inc. Announces Halal Certification of Its Advanced Cellular Therapeutics, Biomaterial Products and Business Model

Founder recently bought US$70k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: US$0.034 (vs US$0.47 in 3Q 2021)

Imugene’s on CARlytics Combination with Celularity’s Placental-derived off-the-shelf Allogeneic CYCART-19 T Cells Preclinical Data Presented at SITC Annual Meeting

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Celularity Promotes Two Executives in Executive Leadership Team

Celularity Appoints Adrian Kilcoyne as Executive Vice President, Chief Medical Officer and Head of Global Affairs, Patient Safety and Patient Affairs

Celularity appoints Adrian Kilcoyne as chief medical officer

Celularity Inc. Publishes New Data in Frontiers in Immunology Demonstrating Placental-Derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-Infected Cells in Vitro

Celularity Inc. Announces Resignation of Andrew L. Pecora, M.D., F.A.C.P., as Company’s President Effective as of August 31, 2022

Celularity falls after announcing fund raising deal

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Celularity falls 10% on deal for $150M common stock offering

Founder exercised options to buy US$343k worth of stock.

Price target decreased to US$10.60

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Celularity Inc. Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers

Celularity Inc. Announces the Resignation of Andrew L. Pecora as President, Effective from August 31, 2022

Price target increased to US$11.80

Celularity Inc. Announces Board Changes

Celularity Inc. Appoints Diane Parks to Board of Directors

Celularity Inc. announced that it has received $30.000007 million in funding